

# European NOVADUCK

(vector vaccines for ducks)

and

# LyonBioPole GAP

(grippe aviaire pandémique)

research projects



LYONBIOPOLE

Michel Bublot, Merial R&D

Montpellier, December 15, 2008

# European Project NOVADUCK







[www.novaduck.eu](http://www.novaduck.eu)

Novel recombinant DIVA vaccines for ducks



# Why ducks ?

- Waterfowls: reservoir of influenza A
- Grazing ducks
- Important epidemiological role



# NOVADUCK Partners



January 2007



## COORDINATOR



[www.novaduck.eu](http://www.novaduck.eu)

# NOVADUCK WORKPACKAGES (1)

- WP1 – Preparatory phase
- WP2 – Vector vaccine generation:



- Selection of optimal AI gene:

- HA
- VLP retrovirus




- Development of 3 viral vectors

- WP3 – Immune response analysis:



- Humoral, cellular, mucosal
- DIVA test





# NOVADUCK WORKPACKAGES (2)



**CVI**

## - WP4 - Immunogenicity in ducks

- Compare immune response
- Check safety



## - WP5 – Efficacy in ducks

- Challenge model set up
- Compare protective response
- Evaluate potential drift







## NOVADUCK : Novel Avian Influenza DIVA recombinant vaccines for ducks.

WPO2 : Comparaison de l'immunogénicité de différents gènes de l'hémagglutinine de sous-type H5 d'influenzavirus aviaire en utilisant la vaccination ADN chez le canard de barbarie


- Gènes clonés dans un vecteur d'expression

- Expression protéique vérifiée en Immunofluorescence



- **Animaux** : Canards de barbarie EOPS (AFSSA Ploufragan) âgés de 5 semaines (15/groupe)

- **Protocole** :





- **Evaluation de l'immunogénicité** : Tests sérologiques (IHA et SN)







## Comparaison des gènes H5 'optimisés'



### IHA avec Ag LP



### IHA avec Ag HP



### SN avec virus HP



**Conclusions :** **LPAI :** H5 Turkey and Laos : immunogénicité supérieure ou égale à H5 Indonesia  
**HPAI :** H5 Turkey : plus forte immunogénicité envers clades 2.2.1 and 2.2.3






# Evaluation of 3 poxvirus vectors in ducks



CVI

## Serology D28



**Fowlpox (TROVAC)**  
**Canarypox (ALVAC)**  
**Vaccinia (NYVAC)**

**Day-old Muscovy**



**D0: V1 5 log<sub>10</sub>**

**D21: V2 5 log<sub>10</sub>**



Similar immunogenicity of the 3 vectors

# Prime-boost in day-old Pekin ducks



- Dose effect of Fowlpox vector (TROVAC) priming
- Quick decrease of HI titers


# GAP (Pandemic Avian Flu)

LYONBIOPOLE



## Vaccines

sanofi pasteur  
La division vaccins du Groupe sanofi-aventis.






Hôpitaux de Lyon

## Interactome

## Diagnosis



Inserm



# « Heterologous prime-boost » scheme


- V1: Fowlpox-HA vector at day-old
- V2: Inactivated vaccine



V1 à J0	V2 à J21
Inact. H5N9	Inact. H5N9
FP-HA (H5N8)	Inact. H5N9



Ac. Mat. +




# Prime-boost principle


## 1. Different antigen presentation

- **Fowlpox**: Cell-Mediated Immunity
- **Inactivated**: Humoral Immunity

## 2. Boost directed to protective antigen (HA)



## 3. Boost with a different HA to increase response against conserved epitopes (broader response)



$B + B \Rightarrow B$ mainly	(2 shots of inact.)
$AB + AB \Rightarrow A + B$ mainly	(2 shots of biv. inact.)
$A + B \Rightarrow AB + ABC$	<b>(prime-boost)</b>

Bublot *et al.* (2008) Res. Sign Post 37/661(2), 117-136





# Prime-boost concept

- **Advantages:**

- 1st vaccination at the hatchery ⇒ Early onset
- Only 1 administration with adjuvant at the farm
- Broader antibody response
- Multispecies (chickens & ducks)
- Lower risk of influenza drift ???

- **Future:**

- Evaluate the boost with subunit HA protein (DIVA)



# Conclusion

- Benefits of collaborative projects
- Promising prime-boost strategy

